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Olson et al. describe a previously
unknown HDAC-independent
mechanism by which several known
hydroxamate-based HDAC inhibitors can
reduce oxidative stress. The mechanism
seems to involve the reduction of
intracellular H2O2 levels following the
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Histone deacetylase (HDAC) inhibitors have shown
enormouspromise for treatingvariousdiseasestates,
presumably due to their ability to modulate acetyla-
tion of histone and non-histone proteins. Many of
these inhibitors contain functional groups capable of
strongly chelating metal ions. We demonstrate that
several members of one such class of compounds,
the hydroxamate-basedHDAC inhibitors, can protect
neurons from oxidative stress via an HDAC-inde-
pendent mechanism. This previously unappreciated
antioxidant mechanism involves the in situ formation
of hydroxamate-iron complexes that catalyze the
decomposition of hydrogen peroxide in a manner
reminiscent of catalase. We demonstrate that while
many hydroxamate-containing HDAC inhibitors dis-
play a propensity for binding iron, only a subset
form active catalase mimetics capable of protecting
neurons from exogenous H2O2. In addition to their
impact on stroke and neurodegenerative disease
research, these results highlight the possibility that
HDAC-independent factors might play a role in the
therapeutic effects of hydroxamate-based HDAC
inhibitors.
INTRODUCTION
The deleterious effects of oxidative stress contribute to the
neuronal death associated with a variety of brain disorders in-
cluding Parkinson’s disease, Alzheimer’s disease, and stroke
(Uttara et al., 2009). It is believed that these effects can be miti-
gated by promoting oxidative defense mechanisms through the
manipulation of epigenetic factors (Schweizer et al., 2013). This
conclusion is due in large part to the effectiveness of small
molecule inhibitors of histone deacetylases (HDACs) in various
models of neuroprotection (Ryu et al., 2003; Kim et al., 2007;
Shein et al., 2009; Butler et al., 2010; Fleiss et al., 2012; Lu
et al., 2013). HDACs catalyze the removal of acetyl groupsChemistry & Biology 22,from the ε-nitrogens of lysine residues, a posttranslational modi-
fication that can profoundly affect cellular processes ranging
from cytoskeletal reorganization (Piperno et al., 1987) to gene
expression (Spange et al., 2009). With the exception of the nico-
tinamide adenine dinucleotide-dependent sirtuins (class III),
HDACs are metalloenzymes (class I, HDACs 1, 2, 3, and 8; class
II, HDACs 4, 5, 6, 7, 9, and 10; class IV, HDAC11). This means
that the vast majority of known HDAC inhibitors (HDACi) contain
a metal-binding group of varied chelating ability (e.g., hydroxa-
mic acids, o-aminoanilides, ketones, etc.) (Pan et al., 2012);
however, the chemical properties associated with such func-
tional groups are often overlooked when studying the biological
effects of HDACi. Herein, we demonstrate that the iron-binding
ability of several known hydroxamate-based HDACi is neces-
sary, but not sufficient, to explain their capacity to protect neu-
rons from exogenous H2O2. Instead, our data suggest that
only a subset of these iron-binding small molecules can form
complexes capable of catalyzing the disproportionation of
H2O2 into water and the less potent cellular oxidant, molecular
oxygen.
RESULTS AND DISCUSSION
TheDevelopment ofChemical Tools for StudyingHDACs
As part of our general interest in using chemical tools to study
the function of the various Zn-dependent HDAC isoforms
(Gregoretti et al., 2004), we amassed a collection of HDACi
and analogs, including appropriately designed negative control
compounds, belonging to different chemical classes with vary-
ing potencies and selectivities (Figure 1). Initially, we tested
several of these compounds in a glutathione (GSH) depletion
assay that models oxidative stress (Murphy et al., 1990; Ratan
et al., 1994; Ratan and Baraban, 1995) and found that many
were effective in protecting murine cortical neurons from death
(Figure S1). The non-selective hydroxamate-based inhibitors
were particularly potent as they conferred full protection at nano-
molar concentrations.
Several Hydroxamate-Based HDACi Exhibit
HDAC-Independent Antioxidant Properties
Because the GSH depletion assay requires the use of imma-
ture neurons lacking functional N-methyl-D-aspartate (NMDA)439–445, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 439
Figure 1. Chemical Tools for Studying the
Role of HDACs in Neuroprotection
(A and B) Chemical structures (A) and HDAC po-
tencies (IC50s) (B) of chemical tools used in this
study. Absolute potency values can be found in
Table S1. *Denotes a negative control compound
based on the parent structure. See also Table S1.receptors to prevent excitotoxicity (Murphy et al., 1990), we
next decided to test the neuroprotective properties of these
HDACi by subjecting fully mature cortical neurons to H2O2 (Fig-
ure 2A), a direct oxidative insult that mimics the concentration
of H2O2 released during stroke (Hyslop et al., 1995). Surpris-
ingly, we found that the non-selective inhibitor LBH-589 was
able to fully protect neurons from a H2O2 insult, although
other non-selective inhibitors with similar potencies could not
(Figure 2A). We ruled out the possibility of differential toxicity
accounting for the observed neuroprotection because in the
absence of insult, these compounds did not cause any cell
death at the concentrations and time frame employed in the
assay (Figure 2C). These results provided the first piece of ev-
idence suggesting that there might be multiple mechanisms by
which hydroxamate-based HDACi can exert neuroprotective
effects.
Upon closer examination, we discovered that the non-selec-
tive HDAC inhibitor LBH-589, the HDAC8-selective inhibitor
PCI-34051 (Balasubramanian et al., 2008), and the HDAC6-
selective inhibitor tubastatin A (Butler et al., 2010) protected
neurons from H2O2 at relatively high concentrations (>10 mM)
(Figure 2B), results that seemed inconsistent with their excep-
tional HDAC potencies (half-maximal inhibitory concentration440 Chemistry & Biology 22, 439–445, April 23, 2015 ª2015 Elsevier Ltd All rights reserved[IC50] < 15 nM). Furthermore, we recently
reported that PCI-34051 protects neu-
rons from GSH depletion via an opaque
but HDAC-independent mechanism (Slei-
man et al., 2014), and we hypothesized
that such a mechanism might play a role
in the neuroprotective effects of LBH-
589 and tubastatin A as well. This hypoth-
esis was supported by the fact that other
HDAC6- (i.e., BRD3493 and BRD9757)
and HDAC6/8-selective (i.e., BRD3954)
inhibitors were unable to protect cortical
neurons from the deleterious effects of
H2O2 (Figure 2A), even at concentrations
known to induce tubulin acetylation (Wag-
ner et al., 2013; Olson et al., 2013), the
known cellular substrate for HDAC6 (Hub-
bert et al., 2002).
To establish whether or not the in-
hibition of HDAC6 and/or HDAC8 is
involved in neuroprotection, we synthe-
sized BRD3067 and BRD3811 (Olson
et al., 2014) as negative control com-
pounds structurally related to tubastatin
A and PCI-34051, respectively. These
compounds contain a singlemethyl group
ortho to the hydroxamic acid moiety thatprecludes entry into the active site of the enzyme but does not
interfere with the metal-chelating ability of the hydroxamate.
Both negative control compounds protected neurons from
H2O2 (Figure 2A) despite their inability to inhibit HDACs (Fig-
ure 1B), thus demonstrating that structurally related hydroxa-
mate-based HDACi exert neuroprotective effects via an HDAC-
independent mechanism. In addition, we noted that BRD3493
and BRD9287, two analogs of tubastatin A and PCI-34051,
respectively, did not exhibit any neuroprotective properties (Fig-
ure 2A). These compounds retained the phenyl or indole hy-
droxamic acid portion of their respective parent compound but
lacked the associated aromatic methylene substituent. We
were intrigued as to why such small structural changes would
have such dramatic effects on the ability of these compounds
to protect neurons from oxidative stress and we set out to link
these structural characteristics to the differential functional re-
sponses elicited by these compounds.
Next, we found that LBH-589, tubastatin A, and PCI-34051
were able to protect rat cortical neurons from a H2O2 insult
even in the presence of actinomycin D or cycloheximide (Fig-
ure 2D), confirming that the mechanism by which these small
molecules protect cells from H2O2 is independent of trans-
cription and translation, and thus, not dependent on gene
Figure 2. Hydroxamate-Based HDAC Inhib-
itors Protect Murine Cortical Neurons from
Oxidative Stress through an HDAC-Inde-
pendent Mechanism
(A) Rat E18 cortical neurons were simultaneously
treated with 150 mM H2O2 and compounds
(30 mM). Cell death was assayed 24 hr later via
an MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide) assay. Several negative
control compounds based on the structures of
known HDACi exhibited robust protection of
cortical neurons from H2O2-induced death, des-
pite lacking HDAC inhibitory activity.
(B) Protection from H2O2 occurs in a dose-
dependent manner.
(C) Compounds do not induce cell death at the
highest concentration (30 mM) and longest time
frame (24 hr) employed in these assays.
(D) Protection from H2O2 occurs independent
of transcription or translation. Assays were per-
formed in the presence of either 2 mg/ml actino-
mycin D or 10 mg/ml cycloheximide. Data are
shown as means ± SEM. Significance was es-
tablished relative to DMSO + H2O2. *p % 0.05,
**p% 0.01, ***p% 0.001, ****p% 0.0001 from the
Tukey post hoc test following one-way ANOVA.
See also Figure S1.expression changes resulting from HDAC inhibition. Further-
more, we noticed that the neuroprotective effects of PCI-
34051 and BRD3811 could be attenuated by the addition of
ZnCl2 (unpublished data), suggesting an important role for
metal chelation. This hypothesis was further strengthened by
the observation that only compounds containing hydroxamicChemistry & Biology 22, 439–445, April 23, 2015acids, and not other metal-binding
groups such as o-aminoanilides or ke-
tones, were protective against H2O2 (Fig-
ure 2A). In addition, it should be noted
that the neuroprotective properties of
these compounds seem to be limited
to oxidative stress as PCI-34051 was
unable to protect neurons from other
forms of stress, including treatment with
NMDA, glutamate, 6-hydroxydopamine,
3-nitropropionic acid, camptothecin, or
staurosporine (unpublished data).
Not All Hydroxamate-Based HDACi
Are Strong Binders of Iron
As it is well established that Fenton
chemistry can play a critical role in delete-
rious oxidative stress (Kohen and Nyska,
2002; Prousek, 2007; Thomas et al.,
2009), and these compounds are neuro-
protective at the approximate concentra-
tion of free chelatable cellular iron (Fiedler
et al., 2007), we reasoned that the metal-
chelating property of these hydroxamic
acids is crucially important for protecting
neurons from a H2O2 insult. To test this
hypothesis, we measured the ability ofeach of these compounds to bind iron using an in vitro calcein
assay (Figure 3) and found that several of them could bindmetals
in cells (Figure S2A) (Cabantchik et al., 1996). Briefly, upon bind-
ing to iron, the fluorescence of calcein is partially quenched.
Compounds that are strong chelators of iron can effectively
compete with calcein for the available iron, ultimately decreasingª2015 Elsevier Ltd All rights reserved 441
Figure 3. HDAC Inhibitors Display Differential Abilities to Bind Iron
In vitro calcein fluorescence was partially quenched upon the addition of
FeSO4. Several, but not all, compounds were able to restore calcein fluores-
cence through competitive iron binding. Data are shown as means ± SEM.
Significance was established relative to DMSO + FeSO4. *p % 0.05, **p %
0.01, ***p% 0.001, ****p% 0.0001 from the Tukey post hoc test following one-
way ANOVA. See also Figure S2.the amount of iron-bound calcein and increasing calcein fluores-
cence. Somewhat surprisingly, we found that not all hydroxamic
acid-containing compounds were able to effectively bind iron
(Figure 3). For instance, BRD3493 and BRD9287, the analogs
of tubastatin A and PCI-34051, respectively, which did not
exhibit any neuroprotective properties, also did not effectively
compete with calcein for free chelatable iron. Not surprisingly,
the compounds that were the most effective iron binders were
also the best at protecting cortical neurons from an Fe/8-hydrox-
yquinoline complex, a membrane permeable iron insult (Jonas
and Riley, 1991) (Figure S2B). This effect could be due to either
the sequestration of redox active iron within the cell or the rapid
stripping of iron from 8-hydroxyquinoline to form cell-imperme-
able complexes. Regardless, these studies confirm the results
of our in vitro iron-binding assays.442 Chemistry & Biology 22, 439–445, April 23, 2015 ª2015 ElsevierThe Ability to Bind Iron is Not Sufficient to Protect
Neurons From H2O2
While all compounds protective in the H2O2 neuroprotection
assay were effective chelators of iron, the non-selective inhibitor
scriptaid and its structurally related negative control nullscript
were able to bind iron and protect cells from an iron insult (Fig-
ure 3; Figure S2B) but were unable to protect neurons from
H2O2 (Figure 2). Therefore, we deemed iron chelation necessary
but not sufficient to protect neurons from exogenous H2O2. It
is possible that a reduction in Fenton chemistry plays a small
role in the neuroprotective effects of these compounds; how-
ever, based on the scriptaid and nullscript results, we hypothe-
sized that the complexes formed upon iron chelation might be
exerting a more profound effect than simply the act of seques-
tering iron itself.
HDACi Display Catalase-Like Activity in the Presence
of Iron
Inspiredbyprevious reports (Baker et al., 1998;Rauenetal., 2004;
Sustmann et al., 2007), we hypothesized that some of these
hydoxamic acid-containing compounds might form catalase
mimetic complexes upon binding intracellular iron, thus facili-
tating the degradation of H2O2 and making them particularly
well suited to protect neurons from an H2O2 insult. To test this
idea, we performed an in vitro assay (Figure 4A) that uses chemi-
luminescent detection of H2O2 (Figure S3A) to measure changes
in H2O2 concentration and compared these hydroxamate-iron
complexes with the known catalase mimetic EUK 134 (Baker
et al., 1998). Iron sulfate (FeSO4) itself causes a slight reduction
in H2O2 levels after 2 hr. However, when FeSO4 is combined
with certain hydroxamic acid-containingHDACi or analogs, these
compounds serve as ligands for the iron and form complexes,
leading to the rapid decomposition of H2O2 (Figure 4C). Although
the most potent complexes caused the final concentration of
H2O2 to fall below the linear range of the assay (Figure S3B), we
were able to estimate that 0.00005 equivalents of one of these
iron complexes (e.g., iron complexes utilizing LBH-589 or PCI-
34051 as ligands) relative to H2O2 is able to reduce the levels of
oxidant by six orders of magnitude (from >1 M to 1 mM) in only
2 hr. Importantly, in the absence of additional FeSO4, these com-
pounds do not cause the decomposition of H2O2 (Figure S3C),
thus indicating that it is the complexes, and not the ligands them-
selves, that are responsible for performing the catalysis.
It is important to note that not all hydroxamic acids are
capable of serving as a precursor to a catalase mimetic com-
plex. Some do not bind iron strongly (e.g., BRD9287, BRD3493,
and BRD9757), while others are strong iron binders, yet the
complexes they form are unable to perform the catalysis (e.g.,
scriptaid and nullscript). While the exact structures of these
hydroxamate-based catalase mimetic complexes have not yet
been elucidated, all competent ligands share similar structural
features. These ligands are invariably either an aryl or cinnamyl
hydroxamic acid with a pendant substituent. For reasons that
are unclear, alkyl and alkenyl hydroxamic acids in the presence
of iron do not display catalase-like activity.
The reaction of several of these catalase mimetic complexes,
such as the one formed from PCI-34051 and iron, with H2O2 is so
vigorous that the product of that reaction (i.e., molecular oxygen)
is immediately visualized as obvious effervescence (Figure 4B)Ltd All rights reserved
Figure 4. Hydroxamate-Based HDAC Inhibitor-Iron Complexes Catalyze the Decomposition of H2O2 and Mitigate Intracellular ROS Levels
(A) Schematic depicting an in vitro H2O2 decomposition assay.
(B) Reactions employing hydroxamate-based HDACi-iron complexes capable of catalyzing the disproportionation of H2O2 into water and gaseous O2 produce
effervescence.
(C) Some hydroxamate-basedHDACi, in combinationwith FeSO4, are capable of drastically reducing in vitro levels of H2O2, while others cannot. The black dotted
line indicates the decomposition of H2O2 resulting fromDMSO+ FeSO4 only. Concentrations below the white dotted line fall outside the linear range of this assay.
Data are shown asmean ± SEM. Significance was established relative to DMSO+FeSO4. *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001 from the Tukey post
hoc test following one-way ANOVA.
(D) Rat cortical neurons were treated with HDACi at 30 mM for 24 hr before endogenous levels of intracellular ROS were determined using the ROS-sensitive
fluorescein derivative CM-H2DCFDA. The scale bar denotes 100 mm.
(E) Quantification of endogenous ROS levels shows that the catalase mimetic properties of LBH-589 can reduce endogenous ROS levels. Data are shown as
means ± SEM.
(F) Schematic depiction of a model for an HDAC-independent neuroprotection mechanism.
(G) Summary of neuroprotective effects at either low (%1 mM) or high (R10 mM) concentrations. See also Figures S3 and S4.(Fung andPetrishko, 1973). This is in stark contrast to complexes
formed by compounds like scriptaid, which do not catalyze the
decomposition of H2O2 (Figure 4C) and thus do not cause effer-
vescence (Figure 4B). Importantly, the results of our in vitro H2O2
decomposition assay are in accord with the results of our H2O2Chemistry & Biology 22,neuroprotection assay, that is to say that the compounds that
form complexes capable of catalyzing the decomposition of
H2O2 in vitro are also those that protect cortical neurons from a
H2O2 insult. Although the iron complex of BRD9287 did show
some catalase-like activity in vitro (Figure 4C), it did not in cells439–445, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 443
(Figure 2A). This is likely due to in vitro conditions driving the for-
mation of the catalase mimetic complex. In cells, the low con-
centration of free chelatable iron coupled with the low affinity
of BRD9287 for iron (Figure 3) is likely to preclude the formation
of the active catalyst, thus explaining the inability of BRD9287
to protect neurons from a H2O2 insult (Figure 2A). Therefore,
we propose that hydroxamate-containing molecules must (1)
display a propensity for binding cellular iron and (2) form
iron complexes capable of catalyzing the disproportionation of
H2O2 for these compounds to exhibit sufficient antioxidant prop-
erties to protect cells from exogenous H2O2.
When compared with the state-of-the-art commercially avail-
able catalase mimetic EUK 134 (Baker et al., 1998), a Mn
complex with antioxidant properties that have been shown to
drastically extend the life of Caenorhabditis elegans (Melov
et al., 2000), the hydroxamate-iron complexes described here
display similar catalase-like activity. In fact, they are approxi-
mately ten times more potent than EUK 134, as 1 mM EUK 134
was necessary to produce a decrease in H2O2 concentration
comparable with the decrease produced by 0.1 mM of the hy-
droxamate-iron complexes (Figure 4C). Furthermore, the in situ
formation of catalase mimetic complexes from hydroxamates
confers two obvious advantages over simply utilizing a Mn com-
plex like EUK 134: (1) it obviates the need to introduce toxic
metals into the cells and (2) it has the added benefit of seques-
tering any excess redox active iron that may be engaging in dele-
terious Fenton chemistry.
Next, we assayed the effects of hydroxamate-based HDACi
and associated analogs on cellular levels of reactive oxygen spe-
cies (ROS) using CM-H2DCFDA, a fluorescein derivative with a
fluorescence intensity that is increased in the presence of ROS
(Figure S4). Initially, when rat cortical neurons are treated with
H2O2, levels of cellular ROS appear to decrease (Figure S4).
This somewhat counterintuitive result can be rationalized by a
rapid H2O2-induced increase in antioxidant defense mecha-
nisms. Compounds that form catalase mimetic complexes
in vitro and protect neurons from a H2O2 insult either delay or
completely prevent this initial decrease in fluorescence, presum-
ably by sufficiently lowering intracellular H2O2 levels (Figure S4).
In time, the antioxidant defense mechanisms of cells not treated
with catalase mimetics are overwhelmed and the cells ultimately
succumb to the swelling and rupture characteristic of H2O2-
induced necrosis. Finally, we treated cells for 24 hr (in the
absence of H2O2) with several non-selective HDACi to assess
changes in endogenous levels of ROS. While LBH-589 was
able to lower endogenous ROS levels, the two compounds of
this series that did not form catalase mimetic complexes
in vitro (i.e., scriptaid and suberoylanilide hydroxamic acid) could
not (Figures 4D and 4E), thus confirming that iron sequestration
alone is not sufficient to reduce endogenous ROS levels.
All procedures followed the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved
by either the Massachusetts Institute of Technology or the Weill
Cornell Medical College Animal Care and Use Committees.
SIGNIFICANCE
Our data suggest that hydroxamate-based HDACi can exert
neuroprotective effects via an HDAC-dependent mecha-444 Chemistry & Biology 22, 439–445, April 23, 2015 ª2015 Elseviernism, an HDAC-independent mechanism, or a combination
of both. At low nanomolar concentrations near their HDAC
IC50s, non-selective inhibitors, such as scriptaid, can protect
neurons from GSH depletion via what appears to be an
HDAC-dependent mechanism, a conclusion that is sup-
ported by the fact that no such protection is observed
when the structurally related negative control compound
nullscript is employed. Other HDACi, such as PCI-34051,
protect neurons from oxidative stress at concentrations
much greater than their HDAC IC50s, and these compounds
engage in anHDAC-independentmechanism. Upon entering
the cell, these hydroxamic acids bind to free cellular iron,
potentially mitigating deleterious Fenton chemistry, but
more importantly, forming complexes capable of catalyzing
the disproportionation of H2O2 into water and O2. Hydroxa-
mate-containing compounds that exhibit catalase-like ac-
tivity but not HDAC inhibitor activity, such as BRD3811,
may prove to be useful in the treatment of diseases such
as stroke, as these compounds have powerful antioxidant
properties, and presumably, will not suffer from the HDAC-
related toxicities that have hampered the development of
HDACi as therapeutics. Of course, exploiting such cata-
lase-like antioxidant effects for therapeutic purposes would
necessitate achieving a sufficiently high concentration of
hydroxamate in vivo. The discovery that hydroxamate-based
HDACi can exert neuroprotective effects by forming cata-
lase mimetic complexes in cells lays the foundation for
future studies regarding the HDAC-independent effects of
these important compounds on a variety of disease states
involving oxidative stress, including immunological disor-
ders and cancer.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2015.03.014.
ACKNOWLEDGMENTS
Wewould like to thank T. Hasaka for technical help with imaging experiments,
and L. Gaffney for helpwith illustrations. Furthermore, wewould like to thankR.
Becker, J. Biag,M.Walk, andM.We¨iwer for helpful discussions. This workwas
supported by the Stanley Medical Research Institute, the Burke Foundation,
the NIH (Grant P01 NIA AG014930, Project 1 to RRR), a Miriam and Sheldon
Adelson Medical Research Foundation Grant (to RRR), and a Goldsmith Foun-
dation post-doctoral fellowship (to SFS).
Received: September 22, 2014
Revised: January 26, 2015
Accepted: March 2, 2015
Published: April 16, 2015
REFERENCES
Baker, K., Marcus, C.B., Huffman, K., Kruk, H., Malfroy, B., and Doctrow, S.R.
(1998). Synthetic combined superoxide dismutase/catalase mimetics are pro-
tective as a delayed treatment in a rat stroke model: a key role for reactive ox-
ygen species in ischemic brain injury. J. Pharmacol. Exp. Ther. 284, 215–221.
Balasubramanian, A., Ramos, J., Luo, W., Sirisawad, M., Verner, E., and
Buggy, J.J. (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor
PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026–1034.Ltd All rights reserved
Butler, K.V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., and Kozikowski,
A.P. (2010). Rational design and simple chemistry yield a superior, neuropro-
tective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842–10846.
Cabantchik, Z.I., Glickstein, H., Milgram, P., and Breuer, W. (1996). A fluores-
cence assay for assessing chelation of intracellular iron in a membrane model
system and in mammalian cells. Anal. Biochem. 233, 221–227.
Fiedler, A., Reinert, T., Morawski, M., Bru¨ckner, G., Arendt, T., and Butz, T.
(2007). Intracellular iron concentration of neurons with and without perineuro-
nal nets. Nucl. Instrum. Methods Phys. Res. B 260, 153–158.
Fleiss,B.,Nilsson,M.K.L., Blomgren,K., andMallard,C. (2012).Neuroprotection
by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccha-
ride-sensitised neonatal hypoxic-ischaemic brain injury. J. Neuroinflamm. 9,
1–15.
Fung, D.C., and Petrishko, D.T. (1973). Capillary tube catalase test. Appl.
Microbiol. 26, 631–632.
Gregoretti, I.V., Lee, Y.-M., and Goodson, H.V. (2004). Molecular evolution of
the histone deacetylase family: functional implications of phylogenetic anal-
ysis. J. Mol. Biol. 338, 17–31.
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida,
M., Wang, X.F., and Yao, T.P. (2002). HDAC6 is a microtubule-associated de-
acetylase. Nature 417, 455–458.
Hyslop, P.A., Zhang, Z., Pearson, D.V., and Phebus, L.A. (1995). Measurement
of striatal H2O2 bymicrodialysis following global forebrain ischemia and reper-
fusion in the rat: correlation with the cytotoxic potential of H2O2 in vitro. Brain
Res. 671, 181–186.
Jonas, S.K., and Riley, P.A. (1991). The effect of ligands on the uptake of iron
by cells in culture. Cell Biochem. Funct. 9, 245–253.
Kim, H.J., Rowe, M., Ren, M., Hong, J.S., Chen, P.S., and Chuang, D.M.
(2007). Histone deacetylase inhibitors exhibit anti-inflammatory and neuropro-
tective effects in a rat permanent ischemic model of stroke: multiple mecha-
nisms of action. J. Pharmacol. Exp. Ther. 321, 892–901.
Kohen, R., and Nyska, A. (2002). Oxidation of biological systems: oxidative
stress phenomena, antioxidants, redox reactions, and methods for their quan-
tification. Toxicol. Pathol. 30, 620–650.
Lu, J., Frerich, J.M., Turtzo, L.C., Li, S., Chiang, J., Yang, C., Wang, X., Zhang,
C., Wu, C., Sun, Z., et al. (2013). Histone deacetylase inhibitors are neuropro-
tective and preserve NGF-mediated cell survival following traumatic brain
injury. Proc. Natl. Acad. Sci. USA 110, 10747–10752.
Melov, S., Ravenscroft, J., Malik, S., Gill, M.S., Walker, D.W., Clayton, P.E.,
Wallace, D.C., Malfroy, B., Doctrow, S.R., and Lithgow, G.J. (2000).
Extension of life-span with superoxide dismutase/catalase mimetics.
Science 289, 1567–1569.
Murphy, T.H., Schnaar, R.L., and Coyle, J.T. (1990). Immature cortical neurons
are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake.
FASEB J. 4, 1624–1633.
Olson, D.E., Wagner, F.F., Kaya, T., Gale, J.P., Aidoud, N., Davoine, E.L.,
Lazzaro, F., We¨iwer, M., Zhang, Y.-L., and Holson, E.B. (2013). Discovery of
the first histone deacetylase 6/8 dual inhibitors. J. Med. Chem. 56, 4816–4820.
Olson, D.E., Udeshi, N.D., Wolfson, N.A., Pitcairn, C.A., Sullivan, E.D., Jaffe, J.,
Svinkina, T., Natoli, T., Liu, X., Paulk, J., et al. (2014). An unbiased approach toChemistry & Biology 22,identify endogenous substrates of ‘‘histone’’ deacetylase 8. ACS Chem. Biol.
9, 2210–2216.
Pan, H., Cao, J., and Xu, W. (2012). Selective histone deacetylase inhibitors.
Anticancer Agents Med. Chem. 12, 247–270.
Piperno, G., LeDizet, M., and Chang, X.-J. (1987). Microtubules containing
acetylated alpha-tubulin in mammalian cells in culture. J. Cell Biol. 104,
289–302.
Prousek, J. (2007). Fenton chemistry in biology and medicine. Pure Appl.
Chem. 79, 2325–2338.
Ratan, R.R., and Baraban, J.M. (1995). Apoptotic death in an in vitro model of
neuronal oxidative stress. Clin. Exp. Pharmacol. Physiol. 22, 309–310.
Ratan, R.R., Murphy, T.H., and Baraban, J.M. (1994). Oxidative stress induces
apoptosis in embryonic cortical neurons. J. Neurochem. 62, 376–379.
Rauen, U., Li, T., Sustmann, R., and De Groot, H. (2004). Protection against
iron- and hydrogen peroxide-dependent cell injuries by a novel synthetic
iron catalase mimic and its precursor, the iron-free ligand. Free Radic. Biol.
Med. 37, 1369–1383.
Ryu, H., Lee, J., Olofsson, B.A., Mwidau, A., Dedeoglu, A., Escudero, M.,
Flemington, E., Azizkhan-Clifford, J., Ferrante, R.J., and Ratan, R.R. (2003).
Histone deacetylase inhibitors prevent oxidative neuronal death independent
of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc.
Natl. Acad. Sci. USA 100, 4281–4286.
Schweizer, S., Meisel, A., and Ma¨rschenz, S. (2013). Epigenetic mechanisms
in cerebral ischemia. J. Cerebr. Blood F. Met. 33, 1335–1346.
Shein, N.A., Grigoriadis, N., Alexandrovich, A.G., Simeonidou, C.,
Lourbopoulos, A., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello,
C.A., and Shohami, E. (2009). Histone deacetylase inhibitor ITF2357 is neuro-
protective, improves functional recovery, and induces glial apoptosis following
experimental traumatic brain injury. FASEB J. 23, 4266–4275.
Sleiman, S.F., Olson, D.E., Bourassa, M.W., Karuppagounder, S.S., Zhang,
Y.-L., Gale, J., Wagner, F.F., Basso, M., Coppola, G., Pinto, J.T., et al.
(2014). Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can
mediate neuroprotection independent of HDAC inhibition. J. Neurosci. 34,
14328–14337.
Spange, S., Wagner, T., Heinzel, T., and Kra¨mer, O.H. (2009). Acetylation of
non-histone proteins modulates cellular signalling at multiple levels. Int. J.
Biochem. Cell Biol. 41, 185–198.
Sustmann, R., Korth, H.G., Kobus, D., Baute, J., Seiffert, K.H., Verheggen, E.,
Bill, E., Kirsch, M., and de Groot, H. (2007). Fe(III) complexes of 1,4,8,11-tet-
raaza[14]annulenes as catalase mimetics. Inorg. Chem. 46, 11416–11430.
Thomas, C., Mackey, M.M., Diaz, A.A., and Cox, D.P. (2009). Hydroxyl radical
is produced via the Fenton reaction in submitochondrial particles under oxida-
tive stress: implications for diseases associatedwith iron accumulation. Redox
Rep. 14, 102–108.
Uttara, B., Singh, A.V., Zamboni, P., andMahajan, R.T. (2009). Oxidative stress
and neurodegenerative diseases: a review of upstream and downstream anti-
oxidant therapeutic options. Curr. Neuropharmacol. 7, 65–74.
Wagner, F.F., Olson, D.E., Gale, J.P., Kaya, T., We¨iwer, M., Aidoud, N.,
Thomas, M., Davoine, E.L., Lemercier, B.C., Zhang, Y.-L., and Holson, E.B.
(2013). Potent and selective inhibition of histone deacetylase 6 (HDAC6)
does not require a surface-binding motif. J. Med. Chem. 56, 1772–1776.439–445, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 445
